How much is the latest price of Nilotinib/Nilotinib and how to buy it

Nilotinib/Nilotinib has been launched in China and is included in medical insurance. The latest domestic price is around 3000 to 9000 yuan. The domestic original research version includes 150mg*120 capsules and 200mg*112 capsules. The latest price of the former is around a few thousand yuan, and the latest price of the latter is around 28,000 yuan. In addition, there is an original Indian version of nilotinib overseas, available in 150mg*28 capsules and 200mg*28 capsules. The latest price is 2000 multiples. Patients should choose to purchase according to their own needs.

Nilotinib is improved from the molecular structure of imatinib and has stronger selectivity forBCR-ABLkinase activity. Compared with imatinib, nilotinib is 30 times more potent in inhibiting tyrosine kinases and can effectively inhibit the kinase activity of BCR-ABL mutants that are resistant to imatinib. In addition, it inhibits KIT and PDGFRkinase activities.

The pharmacological effect of Nilotinib is mainly reflected in its ability to target theBcr-Abl protein and inhibit the production of cancer cells by inhibiting this protein containing abnormal chromosomes. Nilotinib can achieve effective therapeutic results when taken twice daily.

In clinical trials, nilotinib has shown significant therapeutic effects. For example, after treatment with Tasigna (trade name of nilotinib), 42% of Gleevec-resistant chronic phase Philadelphia chromosome-positive (Ph+) CML patients will have a reduction or disappearance of abnormal chromosomes. This data demonstrates the effectiveness of nilotinib in treating patients with drug-resistant CML.

Although nilotinib is used in the treatment ofCMLIt has significant effects, but it may also bring some side effects. Common non-hematological adverse reactions include rash, itching, nausea, fatigue, etc., while hematological adverse reactions may include bone marrow suppression, such as thrombocytopenia, neutropenia, and anemia. Therefore, when using nilotinib, patients' hematological parameters need to be carefully monitored and coadministration with other drugs that may affect hematopoietic function needs to be avoided.